Universität zu Köln

Persa, Oana D., Schatton, Kerstin, Ruebben, Albert, Berking, Carola, Erdmann, Michael, Schlaak, Max, Mauch, Cornelia and Steeb, Theresa (2021). Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients. J. Immunother., 44 (6). S. 239 - 242. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1537-4513

Full text not available from this repository.

Abstract

Immune checkpoint inhibitors (ICIs) have tremendously changed the therapeutic landscape of melanoma since they are associated with a durable response, allowing for intentional discontinuation of therapy after complete or partial remission. However, a subset of patients develops a relapse after cessation of ICI treatment and may not respond to reinduction of ICIs. The aim of the present study was to identify risk factors for relapse after intentional discontinuation of ICI therapy. Patients with intentional discontinuation of ICI therapy for metastatic or unresectable melanoma from 5 German university hospitals were analyzed retrospectively. Clinicopathologic and follow-up data of 87 patients were collected and analyzed by univariate and multivariate Cox proportional-hazards models. The following parameters were associated with relapse after cessation of ICI treatment in the univariate Cox regression analysis: concurrent radiotherapy and ICI, best overall response, and presence of brain metastases. Duration of treatment, type of primary tumor, body mass index, programmed-death ligand 1 expression, and lactate dehydrogenase levels did not significantly influence the risk for relapse. In the multivariate analysis, partial remission [hazard ratio 4.217 (95% confidence interval: 1.424-12.49), P=0.009] and stable disease [3.327 (1.204-9.19), P=0.02] were associated with a significant decrease in progression-free survival compared with complete remission. Concurrent radiotherapy and ICI [3.619 (1.288-10.168), P=0.015] are additional independent risk factors for decreased progression-free survival upon ICI discontinuation, whereas the presence of brain metastasis did not reach statistical significance on multivariate analysis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Persa, Oana D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schatton, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Ruebben, Albert UNSPECIFIED UNSPECIFIED UNSPECIFIED Berking, Carola UNSPECIFIED UNSPECIFIED UNSPECIFIED Erdmann, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Schlaak, Max UNSPECIFIED UNSPECIFIED UNSPECIFIED Mauch, Cornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED Steeb, Theresa UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-598447
DOI:	10.1097/CJI.0000000000000375
Journal or Publication Title:	J. Immunother.
Volume:	44
Number:	6
Page Range:	S. 239 - 242
Date:	2021
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1537-4513
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language METASTATIC MELANOMA; THERAPY; PEMBROLIZUMAB; RADIOTHERAPY Multiple languages Oncology; Immunology; Medicine, Research & Experimental Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59844